Martin Shkreli's Stock Predictions Were Accurate Only in the Short Term
www.investigativeeconomics.org
Martin Shkreli is the hedge fund manager infamously known for starting a pharmaceutical company that bought up a life-saving drug under orphan drug status, Daraprim, and hiked the price 4,000 percent.
Martin Shkreli's Stock Predictions Were Accurate Only in the Short Term
Martin Shkreli's Stock Predictions Were…
Martin Shkreli's Stock Predictions Were Accurate Only in the Short Term
Martin Shkreli is the hedge fund manager infamously known for starting a pharmaceutical company that bought up a life-saving drug under orphan drug status, Daraprim, and hiked the price 4,000 percent.